References
- United State Centers for Disease Control and Prevention. CDC’s 2019 Antibiotic Resistance Threats Report; 2019.
- Results of antimicrobial resistance surveillance. 2019 Available from: http://narst.dmsc.moph.go.th/data/AMR%202000-2019-12M.pdf. Accessed 919, 2020.
- Kuo L-C, Lai -C-C, Liao C-H, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect. 2007;13(2):196–198. doi:10.1111/j.1469-0691.2006.01601.x17328733
- Tseng Y-C, Wang J-T, Wu F-L-L, Chen Y-C, Chie W-C, Chang S-C. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2007;59(2):181–190. doi:10.1016/j.diagmicrobio.2007.04.02417662564
- Xiao D, Wang L, Zhang D, Xiang D, Liu Q, Xing X. Prognosis of patients with Acinetobacter baumannii infection in the intensive care unit: a retrospective analysis. Exp Ther Med. 2017;13(4):1630–1633. doi:10.3892/etm.2017.413728413520
- Results of antimicrobial resistance surveillance by location. 2019 Available from: http://narst.dmsc.moph.go.th/data/map2562-06m.pdf. Accessed 919, 2020.
- Puttilerpong C, Chawanasit W, Laohawaleesan W. Antimicrobial use in hospital-acquired pneumonia with multidrug-resistant Acinetobacter baumannii at King Chulalongkorn Memorial Hospital. Thai Pharm Health Sci J. 2011;6(6):32–38.
- Saelao S, Utiswannakul A. Therapy for patient with multidrug-resistant Acinetobacter baumannii pneumonia. J Health Res. 2008;22(3):131–136.
- Kanankaeng W, Sriphong P. Regimens and clinical outcomes of antimicrobial uses in hospital-acquired pneumonia caused by drug resistant Acinetobacter baumannii. Thai J Pharm Pract. 2019;11(3):470–482.
- Jantama SS, Kunawatanakul T, Semaram S, Sangsanon S, Teerawattanasuk N, Jantama K. Detection of carbapenemase and blaOXA-23-like gene in carbapenem-resistant Acinetobacter baumannii at Sunpasitthiprasong Hospital. Isan J Pharm Sci. 2013;9(2):99–109.
- Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis. 2007;11(5):402–406. doi:10.1016/j.ijid.2006.09.01117291803
- Kalin G, Alp E, Akin A, Coskun R, Doganay M. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection. 2014;42(1):37–42. doi:10.1007/s15010-013-0495-y23828559
- Tuon FF, Rocha JL, Merlini AB. Combined therapy for multi-drug-resistant Acinetobacter baumannii infection–is there evidence outside the laboratory? J Med Microbiol. 2015;64(9):951–959. doi:10.1099/jmm.0.00014426220079
- Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015;9(05):476–485. doi:10.3855/jidc.619525989167
- Dejsirilert S, Tiengrim S, Sawanpanyalert P, Aswapokee N, Malathum K. Antimicrobial resistance of Acinetobacter baumannii: six years of National Antimicrobial Resistance Surveillance Thailand (NARST) surveillance. J Med Assoc Thai. 2011;92(8):34.
- Hsu L-Y, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev. 2017;30(1):1–22. doi:10.1128/CMR.00042-1627795305
- Mohd Rani F, ARahman NI, Ismail S, et al. Acinetobacter spp. infections in Malaysia: a review of antimicrobial resistance trends, mechanisms and epidemiology. Front Microbiol. 2017;8(2479). doi:10.3389/fmicb.2017.02479